Skip to main content
OpenTrials
Completed

NCT Number: NCT02785744

Genzyme Osteopenia/Osteoporosis Study

Gaucher disease is a most common genetic metabolic disease characterized by low platelet number, liver and spleen enlargement and various forms of bone diseases including low bone mineral density leading to brittle bones. Various treatment options are now available for this disease.

The purpose of this research study is to determine the prevalence of Gaucher disease in patients with low bone mineral density as observed by DEXA scan, which is a form of X-Ray of the bone.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Gaucher disease is a potential secondary cause of low bone mineral density and it is prevalent among patients with low BMD. This cross sectional design study will measure point prevalence of Gaucher disease in patients with low bone mineral density (BMD).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients > or equal to18 years and able to provide written consent.
  • Patients who have had a bone density test demonstrating T-score <-1.0 on a DEXA scan within the past year or those who are prospectively referred for DEXA scan and who are later identified by their physician to have a DEXA T-score < -1.0.

Exclusion criteria

  • Subject unable to read and sign consent form.
  • Terminally ill subjects or subjects with serious co-morbidities (malignancy), which would limit the ability of the patient to participate in the study.
  • Subjects with the following disorders or exposures
  • Underlying skeletal dysplasia
  • An endocrinologic/metabolic disease known to cause bone demineralization: including parathyroid dysfunction, hyperthyroidism, Cushing syndrome, hypogonadism, panhypopituitarism
  • Cystic Fibrosis
  • Exposure to medications that are known to cause low BMD including chemotherapy within past 2 years, chronic corticosteroid or phenytoin use within past 2 years
  • Radiation exposure within the past 5 years
  • Vitamin D deficiency is not an exclusion criteria as this is highly prevalent in the adult population under investigation as well as in patients with Gaucher disease. (9, 10)
  • Subjects previously diagnosed with Gaucher Disease

Treatment and study plan

Gaucher disease DNA mutation analysis

Other

Primary outcomes

  1. Population prevalence of Gaucher disease among patients with low bone mineral density

    Time frame: 2 Years

Sponsors and collaborators

Lead sponsor

NYU Langone Health

Other

Collaborators

  • Genzyme, a Sanofi Company

Registry information

Official study title

Prevalence of Gaucher Among Patients With Osteopenia/Osteoporosis

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
May 30, 2016
Registry last updated
Mar 23, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.